Fercy Warning Letter Confirms OTC Monograph Fears
This article was originally published in The Gold Sheet
Executive Summary
Drug maker in China found to exploit gap in U.S. regulatory system, exporting OTC monograph drugs without key quality controls or registration until FDA inspection led to import suspension.
You may also be interested in...
Shortcuts Pursued in Effort to Close Compendial Gaps
Officials with FDA, the U.S. Pharmacopeia and the pharmaceutical industry are looking for a quicker way to remedy a situation underscored by the 2008 heparin crisis: the need to update hundreds, perhaps thousands of the compendial standards that the U.S. Pharmacopeia developed and FDA enforces.
‘Shadow’ Factory Challenges Continue For US FDA
Agency wants more information about API suppliers as it winds up case against KV Tech for hidden use of Dr. Reddy’s plant and seeks to find disappearing manufacturer of contaminated OTC eye drops.
US FDA, USP Raise Questions About Valisure’s Assertions Of Benzoyl Peroxide’s Benzene Risks
The US drug regulatory authority and standard-setting organization are evaluating the drug-screening venture’s findings regarding stability and potential carcinogenic risks associated with the widely used acne treatment, which includes Rx formulations.